Current and new oral antithrombotics in nonvalvular atrial fibrillation: A network meta-analysis of 79 808 patients

Heart

Volumn 100, Issue 5, 2014, Pages 396-405

  Dogliotti, Ariel ^a,b   Paolasso, Ernesto ^b,c   Giugliano, Robert P ^d  

^a CREAR   (Argentina)

^b Sanatorio Parque e Instituto Cardiovascular de Rosario   (Argentina)

^c Inst de Invest Microbiol Clinicas   (Argentina)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; COUMARIN; DABIGATRAN; PLACEBO; RIVAROXABAN; WARFARIN;

ADVERSE OUTCOME; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; DOSE RESPONSE; DRUG DOSE COMPARISON; EMBOLISM; HEART ATRIUM FIBRILLATION; HUMAN; META ANALYSIS; MONTE CARLO METHOD; MORTALITY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; EMBOLISM; HUMANS; MODELS, THEORETICAL; STROKE; THROMBOLYTIC THERAPY;

EID: 84896705059     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2013-304347     Document Type: Article

References (50)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67. (Pubitemid 351650486)
2. Wann LS, Curtis AB, January CT, et al. ACCF/AHA/HRS. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57:223-42.
3. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:1070-4.
4. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96. (Pubitemid 46842784)
5. Connolly SJ, Pogue J, Eikelboom J, et al. for the ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
6. Rose AJ, Ozonoff A, Grant RW, et al. Epidemiology of subtherapeutic anticoagulation in the United States. Circ Cardiovasc Qual Outcomes 2009;2:591-7.
7. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066-78.
8. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903-12.
9. Zikria JC, Ansell J. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change. Curr Opin Hematol 2009;16:347-56.
10. Weitz JI. New oral anticoagulants in development. Thromb Haemost 2010;103:62-70.
11. Grip LT, Ruff CT, Giugliano RP. New oral antithrombotic strategies: 2013 update on atrial fibrillation. Hot Top Cardiol 2013;31:7-18.
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. for the RE-LY steering committee and investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
13. Patel MR, Mahaffey KW, Garg J, et al. for the ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91.
14. Granger CB, Alexander JH, McMurray JJ, et al. for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92.
15. Connolly SJ, Eikelboom J, Joyner C, et al. AVERROES steering committee and investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
16. Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clin Cardiol 2013;36:61-7.
17. Network meta-analysis for indirect treatment comparisons. Thomas Lumley. Stat Med 2002;21:2313-24.
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
19. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. (Pubitemid 37088507)
20. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
21. van Valkenhoef G, Lu G, de Brock B, et al. Automating network meta-analysis. Res Syn Meth 2012;3:285-99.
22. Dias S, Welton N, Caldwell D, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932-44.
23. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991;84:527-39.
24. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342:1255-62.
25. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999;319:958-64. (Pubitemid 29469394)
26. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-12.
27. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am Heart J 1999;138:137-43. (Pubitemid 29331134)
28. Antithrombotic Therapy in Atrial Fibrillation Study Group. The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin. Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:295-8.
29. Rash A, Downes T, Portner R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO). Age Ageing 2007;36:151-6. (Pubitemid 46455393)
30. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost 2010;104:1106-15.
31. Harenberg J, Marx S, Diener HC, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients withatrial fibrillation using network meta-analysis. Int Angiol 2012;31:330-9.
32. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:711-19.
33. Biondi-Zoccai G, Malavasi V, D'Ascenzo F, et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth 2013;5:40-54.
34. Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:480-6.
35. Lip GY, Larsen TB, Skjøth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738-46.
36. Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 2012;345:e7097.
37. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost 2012;108:476-84.
38. Wessler JD, Grip LT, Mendell J, et al. The P-Glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013;61:2495-502.
39. Hankey G, Eikelboom J. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation 2011;123:1436-50.
40. Legrand M, Mateo J, Aribaud A, et al. The use of dabigatran in elderly patients. Arch Intern Med 2011;171:1285-6.
41. Cotton BA, McCarthy JJ, Holcomb JB. Acutely injured patients on dabigatran. N Engl J Med 2011;365:2039-40.
42. Lu G, DeGuzman F, Karbarz MJ, et al. Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein (r-Antidote, PRT064445). Presented at the European Society of Cardiology Congress 2011. Paris, France.
43. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124:1573-9.
44. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1: 175-9. (Pubitemid 19038801)
45. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.. N Engl J Med 1990;323:1505-11.
46. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
47. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343:687-91.
48. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: second copenhagen atrial fibrillation, aspirin, and anticoagulation study. Arch Intern Med 1998;158:1513-21. (Pubitemid 28340984)
49. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan atrial fibrillation stroke trial. Stroke 2006;37:447-51. (Pubitemid 43732003)
50. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007;370:493-503. (Pubitemid 47212371)